LifeVantage

LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs. The company was founded in June 1988 and is headquartered in Sandy, UT.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

LifeVantage reports 7.5% revenue growth, eyes expansion into new markets

LifeVantage's Q1 2023 results reflect strong revenue growth driven by the Americas region and successful product launches. The company's LV360 initiative and new compensation plan have shown promising results. However, challenges in the Asia Pacific and Europe region need to be addressed. The fiscal 2023 outlook presents opportunities for continued growth and expansion into new markets.

LifeVantage reports revenue growth in Q2, driven by LV360 strategy

LifeVantage's Q2 saw revenue growth, improved engagement, and successful resolution of supply chain challenges. The introduction of LV360 and product innovations drove performance. Challenges in supply chain management persist, but opportunities for growth are present.

LifeVantage reports revenue growth and product innovation in Q3

LifeVantage's Q3 performance reflects revenue growth, strong financials, and product innovation, with a focus on market expansion.
While challenges exist in regional revenue declines and market uncertainties, the company's strengths in the Americas region and product launches offer growth opportunities.
Maintaining financial stability, enhancing consultant growth, and leveraging new products position LifeVantage for continued success and market leadership.
Overall, LifeVantage's strategic initiatives and financial performance indicate a resilient business model with growth potential and shareholder value.

LifeVantage reports strong Q4 earnings, unveils special dividend for shareholders

LifeVantage's Q4 2023 results reflect robust revenue growth and improved profitability, driven by strategic initiatives and product performance. The company's commitment to shareholder value through dividends and its transformation plan underscores a positive outlook for future growth. While challenges exist, opportunities in product innovation and market expansion position LifeVantage well for continued success.

LifeVantage posts robust Q1 results, eyes international growth opportunities

LifeVantage delivered a strong Q1 2024 performance with revenue growth and improved profitability, driven by successful product sales and international expansion.
Despite challenges like currency fluctuations, the company's financial stability, strategic capital allocation, and growth outlook position it well for future success.
Opportunities in product innovation, international markets, and strategic investments underscore potential avenues for continued growth and value creation for shareholders.
Investors can be optimistic about LifeVantage's trajectory, supported by its solid financial foundation and clear strategic focus on maximizing shareholder value.

LifeVantage reports strong Q2 earnings, eyes growth through product innovation

LifeVantage showcased robust financial performance with notable EBITDA growth and revenue per consultant increase, despite a slight revenue decline.
The company's focus on product innovation, market expansion, and shareholder value enhancement positions it well for future growth and competitiveness.
Strategies to address revenue challenges, capitalize on growth opportunities, and navigate market dynamics will be crucial for sustained success.

LifeVantage reports robust Q3 performance amidst revenue challenges and growth opportunities

LifeVantage demonstrated strong operational performance and profitability improvements in Q3, despite revenue challenges.
The company's focus on consultant enrollment, new product launches, and financial stability are key strengths.
While facing revenue and margin pressures, LifeVantage has opportunities to drive growth through market expansion and product optimization.
Strategic initiatives to address challenges and capitalize on opportunities will be crucial for sustained success in future quarters.

LifeVantage reports Q4 results, eyes growth with loyalty programs

LifeVantage's Q4 2024 performance showed revenue decline but improved margins and strategic initiatives.
Strengths lie in loyalty program enhancements, positive financials, and a promising outlook for fiscal 2025.
Challenges include leadership changes, revenue decline, and the need for sustained growth in active accounts.
Opportunities exist in product launches, retention strategies, and market expansion for the company's growth.
headline

LifeVantage reports robust Q1 earnings, eyes international expansion for growth

LifeVantage's Q1 2025 showcased strong profitability despite revenue decline, driven by the successful MindBody GLP-1 System launch.
Guidance for fiscal 2025 indicates a positive outlook with revenue and EBITDA projections, supported by plans for international product expansion.
While facing revenue challenges, the company's focus on innovation, market demand, and strategic growth initiatives present opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.

Rare Key Ingredient Red Quinoa Activates Natural Collagen Synthesis and Increases Collagen Density by 42% Rare Key Ingredient Red Quinoa Activates Natural Collagen Synthesis and Increases Collagen Density by 42%

LifeVantage Hosts Activate 2022, Introduces Activating TrueScience® Liquid Collagen to U.S. Market

29% net cash of current market capital. Announced first quarterly dividend of $0.03 per share.

LifeVantage: Soft Quarter, New Dividend Policy, EPS +9% Than Street Expectations

LifeVantage Corporation (NASDAQ:LFVN ) Q3 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - CEO Carl Aure - CFO Conference Call Participants Doug Lane - Lane Research Anthony Chiarenza - Key Equity Investors Operator Good day, ladies and gentlemen. Thank you for standing by.

LifeVantage Corporation (LFVN) CEO Steve Fife on Q3 2022 Results - Earnings Call Transcript

SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced that the Company's Board of Directors has approved the initiation of a quarterly cash dividend per share of common stock. The initial quarterly dividend of $0.03 per share of common stock will be paid May 31, 2022 to all stockholders of record at the close of business on May 17, 2022.

LifeVantage Declares First Quarterly Dividend

Initiates first quarterly dividend of $0.03 per common share Initiates first quarterly dividend of $0.03 per common share

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2022

SALT LAKE CITY, April 19, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its third quarter ended March 31, 2022, after the stock market closes on Tuesday, May 3, 2022. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce Third Quarter Fiscal Year 2022 Results on May 3, 2022

SALT LAKE CITY, Feb. 17, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Cindy Latham to the Company's Board of Directors. Latham is a senior-level marketing executive with over 30 years of experience leading global marketing, research and development, and product teams in direct selling organizations.

LifeVantage Appoints Cindy Latham to Board of Directors

The stock price of LifeVantage Corp (NASDAQ: LFVN) fell by over 15% during intraday trading today. This is why it happened.

LifeVantage (LFVN) Stock: Why The Price Substantially Fell Today

LifeVantage Corporation's (LFVN) CEO Steve Fife on Q2 2022 Results - Earnings Call Transcript

SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second fiscal quarter ended December 31, 2021.

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2022

SALT LAKE CITY, Jan. 20, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its second quarter ended December 31, 2021, after the stock market closes on Tuesday, February 1, 2022. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce Second Quarter Fiscal Year 2022 Results on February 1, 2022

SALT LAKE CITY, Jan. 10, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) announced that management will participate in the 2022 ICR Conference today, Monday, January 10th, at 9:30 a.m. Eastern Time.

LifeVantage to Participate in the 2022 ICR Conference

SALT LAKE CITY, Nov. 17, 2021 (GLOBE NEWSWIRE) -- As part of its continued global expansion, LifeVantage Corporation (NASDAQ:LFVN) has formally commenced business in the Philippines through its Philippine subsidiary Protandim Philippines Corporation.

LifeVantage Opens for Business in the Philippines

2.9% YoY decline in 3Q21 revenues and adjusted EPS down 8.0% YoY.

LifeVantage: Soft Quarter, 8x P/E & 14% FCF Yield Plus Buybacks Leads To 51% Upside

LifeVantage Corporation (LFVN) CEO Steve Fife on Q1 2022 Results - Earnings Call Transcript

LifeVantage Corp (NASDAQ: LFVN) has appointed Carl Aure as Chief Financial Officer effective October 25, 2021. Aure has more than 24 years of finance and accounting experience, including over 15 years in the direct selling industry.

LifeVantage Appoints Carl Aure As Finance Chief

SALT LAKE CITY, Oct. 25, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer. Mr. Aure brings more than 24 years of finance and accounting experience including over 15 years in the direct selling industry. He will join the Company on October 25, 2021.

LifeVantage Appoints Carl Aure as Chief Financial Officer

SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its first quarter ended September 30, 2021, after the stock market closes on Thursday, November 4, 2021. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce First Quarter Fiscal Year 2022 Results on November 4, 2021

68% net income CAGR over the last 4 years. 24% net cash, 12% FCF yield.

LifeVantage: 24% Net Cash, 12% FCF Yield And 8x P/E Make This Company Worth A Buy

LifeVantage Corp (NASDAQ: LFVN) reported a fourth-quarter FY21 sales decline of 7.7% year-on-year, to $54.8 million, beating the analyst consensus of $52.6 million. Revenue in the Americas fell 9.6% Y/Y, and Asia/Pacific & Europe region decreased 3.3%.

LifeVantage Q4 Result Tops Consensus, Provides Mixed FY22 Outlook

LifeVantage Corporation (LFVN) CEO Steve Fife on Q4 2021 Results - Earnings Call Transcript

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2021

LifeVantage's (LFVN) CEO Steve Fife on Q3 2021 Results - Earnings Call Transcript

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2021

LifeVantage Corporation (LFVN) Interim CEO Steve Fife on Q2 2021 Results - Earnings Call Transcript

News for LifeVantage Stock (LFVN)